Solriamfetol

Introduction Overview

Generic Name

solriamfetol

Brand Name

Sunosi

Dosage Form

Oral tablet

Drug Class

Miscellaneous central nervous system agents

Pharmacokinetics

Absorption:
Solriamfetol is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours post-dose. Clinical studies have demonstrated that solriamfetol begins to exert its wake-promoting effects within approximately 1 hour of administration, particularly at the 150 mg dose. The bioavailability of solriamfetol is high, and concomitant food intake does not significantly affect the extent of drug absorption, allowing flexible dosing with or without food.

Distribution:
Solriamfetol displays a moderate volume of distribution, indicating distribution beyond the plasma into tissues, including central nervous system compartments where its pharmacological activity occurs. Protein binding is relatively low, facilitating efficient penetration across the blood-brain barrier to exert its therapeutic effects on neurotransmitter systems associated with wakefulness. Distribution kinetics support once-daily dosing for sustained therapeutic levels throughout the waking period.

Metabolism:
Solriamfetol undergoes minimal hepatic metabolism, which distinguishes it from many CNS stimulants that are extensively metabolized by the liver. This minimal metabolism reduces the risk of drug-drug interactions mediated by hepatic enzyme modulation, particularly cytochrome P450 enzymes. The primary clearance pathway is via renal excretion of the unchanged parent compound, suggesting reliable pharmacokinetics even in the presence of variable hepatic function but necessitating caution in renal impairment.

Elimination:
Elimination of solriamfetol primarily occurs through renal excretion, with approximately 90% of the administered dose excreted unchanged in urine. The elimination half-life ranges from approximately 7 to 8 hours, supporting once-daily dosing in the morning. In patients with impaired renal function, clearance is reduced, necessitating dose adjustments. The predictable elimination profile allows for steady-state achievement within a few days of consistent dosing. The drug’s pharmacokinetics supports a flexible dosing regimen tailored to the patient's wakefulness needs and tolerability.

Dosage Forms

Available Dosage Forms:
Sunosi is available as oral tablets for once-daily administration. Available strengths include 37.5 mg, 75 mg, and 150 mg oral tablets. These formulations enable precise dose titration and flexibility to optimize therapeutic effect and minimize adverse reactions.

Dosages for Adults and Adolescents:
For treatment of excessive daytime sleepiness associated with narcolepsy, the typical initial dose is 75 mg orally once daily upon awakening. After 3 days, the dose may be increased to a maintenance range of 75 to 150 mg once daily, based on clinical response and tolerability. The maximum recommended dose is 150 mg/day. For obstructive sleep apnea/hypopnea syndrome (OSA), the initial dose is 37.5 mg once daily with dose escalation at intervals of at least 3 days as needed and tolerated, up to a maximum of 150 mg/day.

Specific Patient Populations:
Sunosi usage requires special considerations in patients with renal impairment due to its predominant renal elimination. Dose adjustments or alternative treatment options should be considered for moderate to severe renal dysfunction. The drug is not approved for use in pediatric populations younger than 18 years, and safety and efficacy in this group have not been established. Although pregnancy registries collect data on solriamfetol, the safety profile in pregnant or breastfeeding patients remains insufficient; thus, use should be assessed on a case-by-case basis. Elderly patients may require monitoring due to comorbid conditions but do not have specific dose restrictions solely based on age.

Mechanism Of Action

Solriamfetol, the active component of Sunosi, functions as a selective dopamine and norepinephrine reuptake inhibitor. By blocking the reuptake transporters for these two key monoamine neurotransmitters in the central nervous system, solriamfetol increases their synaptic concentrations. Elevated dopamine and norepinephrine availability enhances neurotransmission in wake-promoting neural pathways, thereby improving alertness and reducing excessive daytime sleepiness.

At the molecular level, solriamfetol exhibits a high affinity for the dopamine transporter (DAT) and norepinephrine transporter (NET), inhibiting their function and preventing reabsorption of dopamine and norepinephrine back into presynaptic neurons. This leads to prolonged stimulation of postsynaptic adrenergic and dopaminergic receptors implicated in arousal, attention, and mood regulation. Unlike classical stimulants such as amphetamines, solriamfetol does not induce the release of these neurotransmitters but specifically inhibits their reuptake, contributing to its unique clinical profile.

Solriamfetol’s increase in central dopaminergic and noradrenergic signaling modulates the activity of brain regions such as the locus coeruleus and hypothalamus, which are critical in maintaining wakefulness and circadian regulation. This mechanistic action underpins its efficacy in disorders such as narcolepsy and obstructive sleep apnea-related excessive daytime sleepiness where neural wake-promoting pathways are dysregulated.

Clinical trials have demonstrated that solriamfetol’s wake-promoting effects manifest rapidly and are sustained during the day with once-daily dosing. Compared to other wake-promoting agents like modafinil, solriamfetol's dual reuptake inhibition confers differentiated pharmacodynamic properties, potentially benefiting patients who have an inadequate response to other therapies. Ongoing research explores its neurobehavioral effects and potential application in other CNS disorders involving sleep-wake disturbances.

Pharmacological Actions

Selective inhibition of dopamine and norepinephrine reuptake transporters, increasing their synaptic concentrations.
Promotion of wakefulness and reduction of excessive daytime sleepiness in adult patients.
Modulation of central nervous system pathways implicated in arousal, including the locus coeruleus and hypothalamus.
Enhancement of cognitive alertness and attention without classical stimulant-induced dopamine release.
Minimal potential for interference with hepatic metabolism due to limited biotransformation.
Predominant renal excretion of unchanged drug, influencing dosing in renal impairment.
Lack of significant interaction with cytochrome P450 enzyme system.
Potential to improve functional outcomes in patients with narcolepsy or obstructive sleep apnea–related hypersomnolence.
Lower abuse liability compared with traditional stimulants, though still a controlled substance due to its mechanism.
Does not treat underlying causes of obstructive sleep apnea but improves symptoms of daytime sleepiness.
Rapid onset of action, generally within one hour post-dose for effective wakefulness promotion.
Once-daily dosing convenience aligned with circadian rhythms of wakefulness.
Minimal sedation or rebound hypersomnolence reported with discontinuation.
Moderate cardiovascular effects such as increased blood pressure and heart rate requiring monitoring.
No significant effect on sleep architecture reported in clinical studies.

Therapeutic Or Clinical Uses

Treatment of excessive daytime sleepiness associated with narcolepsy in adults.
Management of excessive daytime sleepiness in adults with obstructive sleep apnea/hypopnea syndrome, as adjunct to primary airway obstruction therapy.
Adjunctive therapy to improve wakefulness in patients despite optimal treatment of underlying sleep disorders.
Alternative wake-promoting agent for patients intolerant or unresponsive to stimulants like modafinil and armodafinil.
Therapeutic option for patients with narcolepsy exhibiting excessive sleepiness who require non-stimulant treatment modalities.
Potential use in sleep-wake disorders related to central nervous system dysfunction, under clinical investigation.
Used in adult patient populations with neurological sleep disorders requiring daytime alertness enhancement.
Off-label consideration in disorders with associated fatigue or hypersomnolence, pending further research.
Clinically effective for improving quality of life and reducing daytime impairment caused by hypersomnolence.
Often combined with primary therapies for obstructive sleep apnea, such as CPAP, to optimize daytime functioning.
Not indicated for treatment of sleep apnea itself but for its secondary somnolent symptoms.
Therapeutic use guided by titration based on patient-specific tolerability and efficacy profile.
May be integrated into comprehensive sleep disorder management plans including behavioral interventions.
Restricted use in pediatric patients due to lack of established safety and efficacy data.
Usage requires assessment of cardiovascular risk factors and monitored blood pressure during therapy.

Side Or Adverse Effects

Trouble sleeping (insomnia) occurring frequently due to stimulant-like CNS activity.
Anxiety symptoms including nervousness, restlessness, or agitation.
Nausea leading to decreased appetite, which may cause weight loss over time.
Headache, ranging from mild to severe, reported as a common adverse effect.
Increased heart rate (tachycardia) and potential palpitations requiring cardiovascular monitoring.
Hypertension or elevation in blood pressure, sometimes necessitating dose adjustment or discontinuation.
Irritability and mood changes, including increased energy that may lead to agitation or irritability.
Potential allergic reactions, including rare cases of hives, swelling, or breathing difficulties.
Psychiatric symptoms such as hallucinations, mania, or psychosis reported in susceptible individuals.
Risk of misuse, dependence, or addiction due to controlled substance classification.
Possible dizziness or lightheadedness, especially when initiating therapy or with dose increases.
Dry mouth and gastrointestinal disturbances including constipation or upset stomach.
Sleep disturbances including delayed sleep onset when dosing taken too late in the day.
Rare but severe neurological adverse effects such as severe headaches or blurred vision.
Withdrawal symptoms or rebound hypersomnolence upon abrupt discontinuation in some cases.

Precautions

Do not use if patient has taken an MAO inhibitor within the past 14 days due to risk of severe interactions.
Use caution in patients with a history of cardiovascular disease, including recent myocardial infarction or stroke.
Monitor blood pressure and heart rate regularly due to potential for hypertension and tachycardia.
Assess renal function prior to treatment and consider dose adjustments in renal impairment.
Avoid use in pediatric patients under 18 years due to lack of safety and efficacy data.
Monitor for psychiatric symptoms including agitation, hallucinations, and mood disturbances.
Patients with a history of substance use disorder should be closely monitored due to abuse potential.
Pregnancy and breastfeeding decisions should weigh potential benefits and risks; registry participation encouraged.
Avoid taking Sunosi within 9 hours of planned bedtime to minimize risk of insomnia.
Do not abruptly discontinue without medical supervision to prevent possible withdrawal effects.
Inform patients about safe storage to reduce risk of theft, misuse, or accidental ingestion.
Caution when used concomitantly with other central nervous system-active drugs to avoid additive effects.
Use should be combined with effective primary treatments for obstructive sleep apnea (e.g., CPAP).
Patients should be advised not to drive or operate machinery until they know how Sunosi affects them.
Dose increases should be gradual and guided by clinical response and tolerability.

Warnings

Sunosi is a Schedule IV controlled substance due to potential for addiction and abuse.
Concomitant or recent use of MAO inhibitors can result in life-threatening hypertensive crisis.
Risk of serious cardiovascular adverse events including increased blood pressure and heart rate.
May cause serious psychiatric adverse reactions such as mania, psychosis, and suicidal ideation.
Not effective for treatment of the underlying airway obstruction in obstructive sleep apnea.
Misuse of Sunosi can lead to overdose or death; keep medication secure and out of reach of others.
Withdrawal or rebound hypersomnolence may occur if the drug is stopped abruptly.
Patients should be monitored for signs of abuse, dependence, and diversion of the medication.
Use during pregnancy only if clearly needed; limited human data available on fetal risk.
Avoid taking doses late in the day to reduce the risk of insomnia and circadian rhythm disruption.
Potential serious allergic reactions requiring immediate medical attention are possible.
Safety and efficacy in pediatric patients younger than 18 years have not been established.
Dose-related adverse events increase at doses above 150 mg/day without added efficacy.
Patients with severe renal impairment require modified dosing or alternative therapies.
Concomitant use with other stimulants increases risk of hypertension and cardiac complications.

Contraindication

Concomitant or within 14 days of monoamine oxidase inhibitor (MAOI) therapy due to risk of hypertensive crisis.
Known hypersensitivity to solriamfetol or any component of the tablet formulation.
Patients with a history of recent myocardial infarction or unstable cardiovascular disease without medical clearance.
Use in pediatric patients under 18 years due to lack of established safety and efficacy.
Severe renal impairment or end-stage renal disease without appropriate dose adjustments or monitoring.
Concomitant use with other controlled substances or CNS stimulants without medical supervision.
Known history of stimulant abuse or addiction without appropriate safeguards and monitoring.
Pregnancy and lactation contraindications should be guided by risk-benefit assessment by healthcare provider.
Severe uncontrolled hypertension or hypertensive crisis history without adequate control.
Patients exhibiting active psychosis or severe psychiatric disorders uncontrolled by treatment.

Drug Interactions

Contraindicated with monoamine oxidase inhibitors (MAOIs) such as isocarboxazid, phenelzine, selegiline within 14 days.
Potential additive hypertensive effects when combined with other sympathomimetic agents or stimulants.
Minimal cytochrome P450 enzyme interaction due to limited metabolism; low potential for many drug interactions.
Caution advised when used with medications affecting renal excretion or function.
Additive central nervous system stimulation when combined with caffeine, amphetamines, or modafinil.
Possible interaction with antihypertensive agents, requiring blood pressure monitoring and dose adjustment.
No significant clinically relevant interaction with common over-the-counter medications documented.
Interactions with serotonergic agents have not been established but monitoring is prudent due to norepinephrine effects.
Concurrent use with medications that prolong QT interval should be approached cautiously.
Potential interference with certain psychiatric medications requiring altered dosing or monitoring.
Interaction with alcohol may potentiate CNS effects and impair alertness; advised to avoid alcohol consumption.
No reported interaction with hormonal contraceptives or vitamins; however, patient counseling recommended.
Herbal supplements affecting CNS function (e.g., St John's Wort) should be used cautiously.
Renally eliminated drugs co-administered may require monitoring due to shared clearance pathways.
Patients should report all concomitant medications to healthcare providers to manage interaction risks.

Preparations Of The Drug

Oral tablets available in multiple strengths: 37.5 mg, 75 mg, and 150 mg for flexible dosing.
Tablets are film-coated for ease of swallowing and stability.
Packaged in blister packs or bottles with child-resistant caps for safety.
Prescribed for once-daily morning administration to align with circadian wakefulness.
Supplied with accompanying patient Medication Guide outlining precautions and proper use.
Storage recommendation: room temperature, protected from moisture and heat.
Provided with patient instructions for appropriate disposal to prevent misuse.
Available by prescription only due to controlled substance classification.
Produced under strict quality control to ensure consistent dosing and purity.
Not formulated as extended or sustained release; immediate release tablets allowing dose flexibility.
Commercial packaging may include varying quantities to accommodate prescription durations.
Supplemental written information for healthcare professionals includes prescribing information and pharmacology.
No known generic equivalents currently available; marketed under brand name Sunosi.
Supports patient adherence through clear dosage strength distinctions and tablet markings.
Formulation designed to minimize gastrointestinal irritation associated with CNS stimulants.